Polycythemia vera: diagnosis, clinical course, and current management

Basit Öğe Kaydı
dc.contributor.authorBuyukasik, Yahya
dc.contributor.authorAli, Ridvan
dc.contributor.authorCem, A. R.
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorYavuz, Selim
dc.contributor.authorSaydam, Güray
dc.date.accessioned2019-10-27T10:45:20Z
dc.date.available2019-10-27T10:45:20Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractVery important developments related to polycythemia vera (PV) have occurred during the last two decades. The discovery of Janus kinase (JAK) 2 mutations has changed both the diagnosis and clinical management of PV. Currently JAK2 molecular testing is essential in the diagnostic work-up and JAK2 mutation positivity is a major diagnostic criterion. The discovery of JAK2 mutations suggested that abnormal JAK-STAT signaling was a pivotal feature in the pathogenesis of Philadelphia-negative myeloproliferative neoplasms. This idea led to the development of JAK inhibitors. Currently ruxolitinib, a JAK1/JAK2 inhibitor, is also approved for PV patients with hydroxyurea resistance or intolerance. International collaborations have made it possible to describe disease characteristics and evolution better. Presently it is possible to quantify the symptomatic burden of the disease and to estimate prognosis. In spite of these developments, management of PV still largely depends on estimation of thromboembolic risk and trying to decrease the risk with or without cytoreductive medications. Different approaches have been proposed by international disease experts for the diagnosis, thromboembolic risk estimation, and drug selection. This paper aims to review clinical aspects of PV and propose a management algorithm. The authors also point to still unresolved questions and unmet needs in diagnosis and management.en_US
dc.identifier.doi10.3906/sag-1806-43en_US
dc.identifier.endpage710en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid30114348en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage698en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1806-43
dc.identifier.urihttps://hdl.handle.net/11454/31132
dc.identifier.volume48en_US
dc.identifier.wosWOS:000441766000002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPolycythemia veraen_US
dc.subjectdiagnosisen_US
dc.subjectprognosisen_US
dc.subjecttreatmenten_US
dc.titlePolycythemia vera: diagnosis, clinical course, and current managementen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu